INT22863

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1990
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 10
Total Number 11
Disease Relevance 10.68
Pain Relevance 1.86

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Apoa1) transport (Apoa1) extracellular space (Apoa1)
extracellular region (Apoa1) nucleus (Apoa1) enzyme binding (Apoa1)
Anatomy Link Frequency
plasma 2
liver 2
Apoa1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 34 99.32 Very High Very High Very High
fibrosis 108 98.12 Very High Very High Very High
Sciatic nerve 2 97.84 Very High Very High Very High
Multiple sclerosis 96 97.78 Very High Very High Very High
Angina 2 95.12 Very High Very High Very High
Central nervous system 14 94.88 High High
Inflammatory response 3 94.56 High High
Pain 10 89.36 High High
Inflammation 26 81.84 Quite High
Demyelination 4 78.24 Quite High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 84 100.00 Very High Very High Very High
Alcoholic Liver Diseases 9 99.90 Very High Very High Very High
Diabetes Mellitus 85 99.82 Very High Very High Very High
Autoimmune Disease 16 99.50 Very High Very High Very High
Rheumatoid Arthritis 34 99.32 Very High Very High Very High
Systemic Lupus Erythematosus 38 99.04 Very High Very High Very High
Injury 8 98.96 Very High Very High Very High
Reprotox - General 1 48 98.28 Very High Very High Very High
Fibrosis 97 98.12 Very High Very High Very High
Demyelinating Disease 118 97.78 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In the study, our data showed elevated serum apoA-I concentrations in MS patients may be an important feature that is different from other autoimmune diseases which had significantly reduced serum apoA-I levels (such as RA and SLE).
Negative_regulation (reduced) of apoA-I associated with multiple sclerosis, autoimmune disease, rheumatoid arthritis and systemic lupus erythematosus
1) Confidence 0.57 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.45 Pain Relevance 0.63
Therefore, a large number of serum apoA-I synthesized by liver will be albe to meet the remyelination during acute phase of MS.
Negative_regulation (number) of apoA-I in liver associated with multiple sclerosis
2) Confidence 0.42 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2860353 Disease Relevance 1.10 Pain Relevance 0.48
In a placebo-controlled study involving 147 postmenopausal women with early breast cancer, exemestane had no major effect on lipid profile except for a modest but significant decrease from baseline in HDL cholesterol (P < 0.001) and apolipoprotein A1 (P = 0.004) [50].
Neg (except) Negative_regulation (decrease) of apolipoprotein A1 associated with disorder of lipid metabolism and reprotox - general 1
3) Confidence 0.15 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001222 Disease Relevance 0.66 Pain Relevance 0
With cilostazol, there was a trend (3%) toward decreased apoB as well as increased apoA1, resulting in a significant (9.8%, P<0.002) increase in the apoA1 to apoB ratio.
Negative_regulation (decreased) of apoA1
4) Confidence 0.14 Published 1998 Journal Arterioscler. Thromb. Vasc. Biol. Section Abstract Doc Link 9848888 Disease Relevance 0.89 Pain Relevance 0.40
In the T-treated group apolipoprotein-A1 (Apo-A1) (treated 99.2 +/- 12 vs controls 116.2 +/- 27.7 g/l, P < 0.01) and high density lipoprotein cholesterol (HDL-C) (treated 1.3 +/- 0.3 vs controls 1.5 +/- 0.4 nmol/l, P < 0.01) were significantly decreased.
Negative_regulation (decreased) of apolipoprotein-A1
5) Confidence 0.03 Published 1998 Journal Clin. Endocrinol. (Oxf) Section Body Doc Link 9828903 Disease Relevance 0 Pain Relevance 0
It was established that changes in the plasma lipid and apoprotein spectrum result in an increase of apo B, decrease of apo 1, increase of apo B/apo A1, decrease of high-density lipoprotein cholesterol (HDLCS) and a different dynamics of HDLCS/apo A1.
Negative_regulation (decrease) of apo 1 in plasma
6) Confidence 0.02 Published 1990 Journal Vrach Delo Section Abstract Doc Link 2339543 Disease Relevance 0.26 Pain Relevance 0.10
We conclude that the dyslipidemic profile characterized by increased triglyceride level, decreased apolipoprotein A1 level and small dense LDL is associated with uncomplicated PVD in both NIDDM and non-diabetic subjects.
Negative_regulation (decreased) of apolipoprotein A1 associated with diabetes mellitus, peripheral arterial disease and disorder of lipid metabolism
7) Confidence 0.02 Published 1998 Journal Atherosclerosis Section Abstract Doc Link 9544725 Disease Relevance 1.96 Pain Relevance 0.09
The intercept and slope between the reference center and other laboratories were excellent for the three proteins with only one decrease for apolipoprotein A1 in a single center using the ADVIA analyzer.
Negative_regulation (decrease) of apolipoprotein A1 associated with disorder of lipid metabolism
8) Confidence 0.02 Published 2002 Journal Comp Hepatol Section Body Doc Link PMC149429 Disease Relevance 0.10 Pain Relevance 0
In both groups those with PVD were found to have significantly elevated triglycerides (2.7 [2.2-3.3] versus 1.9 [1.6-2.2] mmol/l; P < 0.05 in the diabetic group and 2.0 [1.6-2.3] versus 1.4 [1.1-1.5] mmol/l; P < 0.05 in the non-diabetic group), decreased apolipoprotein A1 (124 +/- 3 versus 139 +/- 5 mg/dl; P < 0.01 in the diabetic group and 133 +/- 4 versus 147 +/- 4 mg/dl; P < 0.05 in the non-diabetic group) and decreased LDL particle size (25.4 +/- 0.1 versus 25.8 +/- 0.1 nm; P < 0.01 in the diabetic group and 26.0 +/- 0.1 versus 26.3 +/- 0.1 nm; P < 0.05 in the non diabetic group).
Negative_regulation (decreased) of apolipoprotein A1 associated with hypertriglyceridemia, diabetes mellitus, peripheral arterial disease and disorder of lipid metabolism
9) Confidence 0.02 Published 1998 Journal Atherosclerosis Section Abstract Doc Link 9544725 Disease Relevance 2.42 Pain Relevance 0.08
a significant decrease in plasma apoA-I levels, total cholesterol, and LDL cholesterol

(small particles), compared to the PPARA Leu162 homozygotes (who demonstrated an

Negative_regulation (decrease) of apoA-I in plasma associated with disorder of lipid metabolism
10) Confidence 0.01 Published 2008 Journal PPAR Research Section Body Doc Link PMC2288645 Disease Relevance 0.34 Pain Relevance 0
When compared to alcoholic liver disease the decrease of apolipoprotein A1 was not significant in patients with advanced fibrosis and NAFLD.
Negative_regulation (decrease) of apolipoprotein A1 in liver associated with fatty liver, fibrosis, alcoholic liver diseases and disorder of lipid metabolism
11) Confidence 0.01 Published 2006 Journal BMC Gastroenterol Section Body Doc Link PMC1386692 Disease Relevance 1.50 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox